Bradley Martin
Concepts (384)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 43 | 2026 | 601 | 8.430 |
Why?
| | Chronic Pain | 17 | 2024 | 189 | 5.620 |
Why?
| | Opioid-Related Disorders | 17 | 2024 | 404 | 3.950 |
Why?
| | Drug Overdose | 10 | 2022 | 161 | 3.560 |
Why?
| | Drug Prescriptions | 16 | 2026 | 112 | 3.410 |
Why?
| | Medicaid | 23 | 2021 | 264 | 2.660 |
Why?
| | Alcoholism | 4 | 2022 | 236 | 2.330 |
Why?
| | Tramadol | 3 | 2024 | 30 | 2.320 |
Why?
| | Antipsychotic Agents | 10 | 2018 | 234 | 1.890 |
Why?
| | Retrospective Studies | 47 | 2026 | 6694 | 1.880 |
Why?
| | Asthma | 5 | 2025 | 313 | 1.880 |
Why?
| | Adult | 59 | 2026 | 14205 | 1.680 |
Why?
| | Anticoagulants | 7 | 2025 | 276 | 1.670 |
Why?
| | United States | 54 | 2025 | 5215 | 1.650 |
Why?
| | Humans | 115 | 2026 | 52441 | 1.610 |
Why?
| | Middle Aged | 58 | 2025 | 13133 | 1.550 |
Why?
| | Osteoarthritis, Knee | 3 | 2017 | 97 | 1.440 |
Why?
| | Adrenal Cortex Hormones | 3 | 2025 | 116 | 1.430 |
Why?
| | Pain | 11 | 2022 | 373 | 1.420 |
Why?
| | Female | 77 | 2026 | 28277 | 1.390 |
Why?
| | Young Adult | 29 | 2026 | 4346 | 1.320 |
Why?
| | Health Care Costs | 10 | 2022 | 176 | 1.310 |
Why?
| | Aged | 46 | 2025 | 10242 | 1.310 |
Why?
| | Male | 72 | 2025 | 26874 | 1.290 |
Why?
| | Adolescent | 38 | 2025 | 6713 | 1.280 |
Why?
| | Atrial Fibrillation | 4 | 2016 | 196 | 1.210 |
Why?
| | Viscosupplements | 3 | 2017 | 14 | 1.200 |
Why?
| | Venous Thromboembolism | 3 | 2025 | 80 | 1.180 |
Why?
| | Hyaluronic Acid | 3 | 2017 | 38 | 1.170 |
Why?
| | Mental Disorders | 7 | 2025 | 427 | 1.150 |
Why?
| | Medication Adherence | 6 | 2016 | 133 | 1.120 |
Why?
| | Emergency Service, Hospital | 6 | 2016 | 521 | 1.100 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 223 | 1.060 |
Why?
| | Schizophrenia | 5 | 2009 | 257 | 1.060 |
Why?
| | Cohort Studies | 17 | 2024 | 1576 | 1.020 |
Why?
| | Arthroplasty, Replacement, Knee | 4 | 2017 | 288 | 1.020 |
Why?
| | Analgesics, Non-Narcotic | 3 | 2012 | 118 | 1.000 |
Why?
| | Acetaminophen | 4 | 2015 | 272 | 0.990 |
Why?
| | Substance-Related Disorders | 5 | 2021 | 615 | 0.980 |
Why?
| | Warfarin | 4 | 2016 | 81 | 0.960 |
Why?
| | Patient Compliance | 6 | 2009 | 228 | 0.950 |
Why?
| | Veterans | 10 | 2024 | 573 | 0.920 |
Why?
| | Psychotropic Drugs | 1 | 2025 | 76 | 0.870 |
Why?
| | Metformin | 1 | 2025 | 82 | 0.860 |
Why?
| | Psychotherapy | 1 | 2025 | 112 | 0.840 |
Why?
| | Suicide | 1 | 2025 | 85 | 0.830 |
Why?
| | Prescription Drugs | 6 | 2014 | 40 | 0.820 |
Why?
| | Cost-Benefit Analysis | 5 | 2020 | 271 | 0.810 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2025 | 570 | 0.790 |
Why?
| | Insurance, Health | 7 | 2020 | 132 | 0.780 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 177 | 0.740 |
Why?
| | Arkansas | 14 | 2026 | 2013 | 0.730 |
Why?
| | Neck Pain | 2 | 2021 | 10 | 0.730 |
Why?
| | Back Pain | 2 | 2021 | 39 | 0.720 |
Why?
| | Central Nervous System Stimulants | 1 | 2023 | 198 | 0.720 |
Why?
| | Drug Utilization | 11 | 2017 | 77 | 0.710 |
Why?
| | Hospitalization | 6 | 2016 | 731 | 0.700 |
Why?
| | Arthralgia | 1 | 2021 | 44 | 0.690 |
Why?
| | Professional-Patient Relations | 1 | 2021 | 46 | 0.690 |
Why?
| | Insurance, Pharmaceutical Services | 2 | 2019 | 25 | 0.680 |
Why?
| | Stroke | 3 | 2016 | 527 | 0.680 |
Why?
| | Decision Support Techniques | 3 | 2016 | 73 | 0.670 |
Why?
| | Risk Factors | 15 | 2025 | 3971 | 0.670 |
Why?
| | Databases, Factual | 12 | 2026 | 721 | 0.650 |
Why?
| | Logistic Models | 8 | 2016 | 930 | 0.650 |
Why?
| | Narcotic Antagonists | 2 | 2024 | 150 | 0.630 |
Why?
| | Breast Neoplasms | 4 | 2023 | 1203 | 0.620 |
Why?
| | Naloxone | 1 | 2020 | 85 | 0.610 |
Why?
| | Hydrocodone | 3 | 2024 | 20 | 0.600 |
Why?
| | Oxycodone | 3 | 2024 | 26 | 0.600 |
Why?
| | Legislation, Drug | 1 | 2019 | 17 | 0.590 |
Why?
| | Contraception | 1 | 2019 | 31 | 0.580 |
Why?
| | Proton Pump Inhibitors | 2 | 2016 | 94 | 0.580 |
Why?
| | Follow-Up Studies | 8 | 2024 | 2294 | 0.540 |
Why?
| | Guidelines as Topic | 1 | 2018 | 111 | 0.540 |
Why?
| | Mammography | 1 | 2018 | 97 | 0.540 |
Why?
| | Buprenorphine | 3 | 2024 | 155 | 0.530 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 498 | 0.530 |
Why?
| | Propensity Score | 4 | 2025 | 160 | 0.520 |
Why?
| | Histamine H2 Antagonists | 1 | 2016 | 28 | 0.510 |
Why?
| | Peptic Ulcer | 1 | 2016 | 15 | 0.510 |
Why?
| | Purinergic P2Y Receptor Antagonists | 3 | 2022 | 34 | 0.490 |
Why?
| | Pyridones | 1 | 2016 | 35 | 0.490 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2016 | 20 | 0.490 |
Why?
| | Time Factors | 10 | 2025 | 2987 | 0.480 |
Why?
| | Risk | 4 | 2020 | 315 | 0.480 |
Why?
| | Aged, 80 and over | 15 | 2025 | 3449 | 0.480 |
Why?
| | Inappropriate Prescribing | 1 | 2016 | 24 | 0.470 |
Why?
| | Safety-Based Drug Withdrawals | 1 | 2015 | 7 | 0.470 |
Why?
| | Dextropropoxyphene | 1 | 2015 | 6 | 0.470 |
Why?
| | Insurance Claim Review | 5 | 2010 | 41 | 0.470 |
Why?
| | Health Expenditures | 3 | 2011 | 74 | 0.470 |
Why?
| | Tobacco Use Cessation | 1 | 2015 | 10 | 0.470 |
Why?
| | For-Profit Insurance Plans | 1 | 2015 | 2 | 0.470 |
Why?
| | Brain Ischemia | 2 | 2016 | 168 | 0.460 |
Why?
| | Pyrazoles | 1 | 2016 | 116 | 0.450 |
Why?
| | Mass Screening | 1 | 2018 | 354 | 0.450 |
Why?
| | Quinolines | 1 | 2015 | 44 | 0.450 |
Why?
| | Acetates | 1 | 2015 | 51 | 0.440 |
Why?
| | Stress, Psychological | 1 | 2016 | 275 | 0.440 |
Why?
| | Diabetic Neuropathies | 1 | 2015 | 57 | 0.440 |
Why?
| | Opiate Substitution Treatment | 3 | 2024 | 107 | 0.440 |
Why?
| | Anticonvulsants | 2 | 2006 | 136 | 0.440 |
Why?
| | Insurance Claim Reporting | 2 | 2011 | 11 | 0.430 |
Why?
| | Low Back Pain | 2 | 2025 | 31 | 0.430 |
Why?
| | Critical Illness | 1 | 2016 | 306 | 0.430 |
Why?
| | Curriculum | 2 | 2018 | 406 | 0.420 |
Why?
| | Palliative Care | 1 | 2016 | 194 | 0.420 |
Why?
| | Tobacco Products | 1 | 2015 | 126 | 0.410 |
Why?
| | Pain Management | 1 | 2015 | 187 | 0.410 |
Why?
| | Neoplasms | 1 | 2023 | 1314 | 0.400 |
Why?
| | Postoperative Complications | 3 | 2025 | 1065 | 0.400 |
Why?
| | Injections, Intra-Articular | 3 | 2017 | 38 | 0.400 |
Why?
| | Computers, Handheld | 1 | 2013 | 23 | 0.390 |
Why?
| | Evidence-Based Medicine | 3 | 2014 | 271 | 0.390 |
Why?
| | United States Department of Veterans Affairs | 5 | 2024 | 291 | 0.380 |
Why?
| | Medicare | 7 | 2025 | 281 | 0.380 |
Why?
| | Age Factors | 6 | 2018 | 1120 | 0.380 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2025 | 177 | 0.370 |
Why?
| | Quality-Adjusted Life Years | 3 | 2020 | 67 | 0.370 |
Why?
| | Neuralgia | 2 | 2023 | 68 | 0.370 |
Why?
| | Cross-Sectional Studies | 6 | 2022 | 1677 | 0.370 |
Why?
| | Child | 11 | 2025 | 7194 | 0.360 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 504 | 0.350 |
Why?
| | Case-Control Studies | 7 | 2023 | 1202 | 0.350 |
Why?
| | Brain Neoplasms | 2 | 2025 | 302 | 0.340 |
Why?
| | Community Pharmacy Services | 3 | 2020 | 71 | 0.330 |
Why?
| | Health Personnel | 1 | 2013 | 255 | 0.320 |
Why?
| | Kidney Failure, Chronic | 2 | 2022 | 205 | 0.320 |
Why?
| | Employment | 2 | 2015 | 94 | 0.310 |
Why?
| | Age Distribution | 5 | 2018 | 176 | 0.300 |
Why?
| | Antidepressive Agents | 2 | 2009 | 176 | 0.300 |
Why?
| | Motor Vehicles | 1 | 2009 | 14 | 0.300 |
Why?
| | Automobile Driving | 1 | 2009 | 27 | 0.300 |
Why?
| | Medication Errors | 1 | 2009 | 24 | 0.300 |
Why?
| | Pharmacists | 3 | 2019 | 150 | 0.290 |
Why?
| | Prevalence | 5 | 2018 | 1016 | 0.280 |
Why?
| | Hemorrhage | 3 | 2023 | 225 | 0.280 |
Why?
| | Cost of Illness | 3 | 2013 | 120 | 0.280 |
Why?
| | Lung Neoplasms | 2 | 2025 | 643 | 0.280 |
Why?
| | Physicians, Primary Care | 2 | 2018 | 43 | 0.280 |
Why?
| | Pain Measurement | 6 | 2021 | 263 | 0.280 |
Why?
| | Health Resources | 2 | 2012 | 71 | 0.270 |
Why?
| | College Admission Test | 2 | 2018 | 13 | 0.270 |
Why?
| | Antimanic Agents | 1 | 2007 | 14 | 0.270 |
Why?
| | School Admission Criteria | 2 | 2018 | 34 | 0.260 |
Why?
| | Schools, Pharmacy | 2 | 2018 | 56 | 0.260 |
Why?
| | Markov Chains | 2 | 2020 | 29 | 0.260 |
Why?
| | Pharmaceutical Services | 2 | 2018 | 52 | 0.260 |
Why?
| | Georgia | 6 | 2006 | 41 | 0.260 |
Why?
| | Orthopedic Procedures | 2 | 2017 | 70 | 0.250 |
Why?
| | Constipation | 1 | 2006 | 38 | 0.250 |
Why?
| | Overweight | 1 | 2009 | 230 | 0.250 |
Why?
| | Multivariate Analysis | 4 | 2017 | 601 | 0.250 |
Why?
| | Least-Squares Analysis | 4 | 2011 | 44 | 0.250 |
Why?
| | Longitudinal Studies | 3 | 2026 | 756 | 0.240 |
Why?
| | United States Food and Drug Administration | 4 | 2011 | 89 | 0.240 |
Why?
| | Knee Joint | 2 | 2017 | 165 | 0.240 |
Why?
| | Pancreaticoduodenectomy | 1 | 2025 | 13 | 0.240 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2021 | 211 | 0.240 |
Why?
| | Pancreatectomy | 1 | 2025 | 18 | 0.240 |
Why?
| | Hepatectomy | 1 | 2025 | 25 | 0.240 |
Why?
| | Cranial Irradiation | 1 | 2025 | 24 | 0.230 |
Why?
| | Odds Ratio | 4 | 2020 | 563 | 0.230 |
Why?
| | Students, Pharmacy | 2 | 2018 | 130 | 0.230 |
Why?
| | Risperidone | 2 | 2010 | 25 | 0.220 |
Why?
| | Colectomy | 1 | 2025 | 35 | 0.220 |
Why?
| | North Carolina | 5 | 2011 | 55 | 0.220 |
Why?
| | Polypharmacy | 1 | 2004 | 15 | 0.220 |
Why?
| | Drug Costs | 2 | 2020 | 40 | 0.220 |
Why?
| | Blood Glucose | 2 | 2025 | 483 | 0.210 |
Why?
| | Cross-Over Studies | 1 | 2025 | 236 | 0.210 |
Why?
| | Pregnancy Outcome | 1 | 2026 | 255 | 0.210 |
Why?
| | General Practitioners | 1 | 2023 | 4 | 0.210 |
Why?
| | Severity of Illness Index | 3 | 2017 | 1045 | 0.210 |
Why?
| | Patient Selection | 1 | 2025 | 269 | 0.210 |
Why?
| | Haloperidol | 1 | 2003 | 46 | 0.200 |
Why?
| | Renal Dialysis | 2 | 2022 | 189 | 0.200 |
Why?
| | Pancreatic Neoplasms | 1 | 2025 | 208 | 0.200 |
Why?
| | Motivation | 1 | 2025 | 283 | 0.200 |
Why?
| | Direct Service Costs | 1 | 2003 | 4 | 0.200 |
Why?
| | Controlled Substances | 1 | 2022 | 5 | 0.200 |
Why?
| | Irritable Bowel Syndrome | 1 | 2003 | 17 | 0.200 |
Why?
| | Aftercare | 1 | 2023 | 67 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2014 | 1365 | 0.190 |
Why?
| | Premedication | 1 | 2002 | 18 | 0.190 |
Why?
| | Health Services Needs and Demand | 1 | 2004 | 161 | 0.190 |
Why?
| | Common Cold | 1 | 2002 | 5 | 0.180 |
Why?
| | Bronchitis | 1 | 2002 | 9 | 0.180 |
Why?
| | Thromboembolism | 1 | 2002 | 48 | 0.180 |
Why?
| | Advisory Committees | 3 | 2018 | 74 | 0.180 |
Why?
| | Proportional Hazards Models | 4 | 2017 | 446 | 0.180 |
Why?
| | Liver Neoplasms | 1 | 2025 | 341 | 0.180 |
Why?
| | Accidents | 1 | 2021 | 19 | 0.180 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 114 | 0.180 |
Why?
| | Prescription Drug Misuse | 2 | 2018 | 31 | 0.180 |
Why?
| | Colorectal Neoplasms | 1 | 2025 | 286 | 0.180 |
Why?
| | Depressive Disorder, Major | 2 | 2020 | 148 | 0.180 |
Why?
| | Pregnancy Complications | 1 | 2026 | 399 | 0.180 |
Why?
| | Forecasting | 3 | 2009 | 151 | 0.180 |
Why?
| | Ambulatory Care Facilities | 1 | 2002 | 122 | 0.170 |
Why?
| | Mental Health Services | 1 | 2004 | 207 | 0.170 |
Why?
| | Respiratory Tract Infections | 1 | 2002 | 82 | 0.170 |
Why?
| | Patient Discharge | 1 | 2023 | 320 | 0.170 |
Why?
| | Delivery of Health Care | 2 | 2021 | 317 | 0.170 |
Why?
| | Interprofessional Relations | 2 | 2018 | 91 | 0.170 |
Why?
| | Afghan Campaign 2001- | 2 | 2018 | 39 | 0.170 |
Why?
| | Regression Analysis | 5 | 2013 | 400 | 0.170 |
Why?
| | Obesity | 1 | 2009 | 1176 | 0.160 |
Why?
| | Administration, Oral | 2 | 2016 | 455 | 0.160 |
Why?
| | Decision Making | 5 | 2018 | 273 | 0.160 |
Why?
| | Administration, Intranasal | 1 | 2020 | 30 | 0.160 |
Why?
| | Cardiovascular Diseases | 2 | 2018 | 493 | 0.160 |
Why?
| | Economics, Pharmaceutical | 2 | 2009 | 6 | 0.160 |
Why?
| | Selection Bias | 2 | 2009 | 15 | 0.160 |
Why?
| | Treatment Outcome | 8 | 2025 | 5508 | 0.160 |
Why?
| | Social Media | 1 | 2022 | 120 | 0.160 |
Why?
| | Comparative Effectiveness Research | 2 | 2009 | 51 | 0.150 |
Why?
| | Preventive Health Services | 1 | 2020 | 53 | 0.150 |
Why?
| | Benzodiazepines | 2 | 2018 | 71 | 0.150 |
Why?
| | Child, Preschool | 5 | 2011 | 4046 | 0.150 |
Why?
| | Insurance Coverage | 1 | 2020 | 106 | 0.150 |
Why?
| | Drug Administration Schedule | 3 | 2011 | 370 | 0.150 |
Why?
| | Coronary Restenosis | 1 | 2019 | 39 | 0.150 |
Why?
| | Guideline Adherence | 3 | 2025 | 142 | 0.150 |
Why?
| | Sepsis | 1 | 2021 | 236 | 0.150 |
Why?
| | Pregnancy | 1 | 2026 | 2642 | 0.150 |
Why?
| | Health Care Surveys | 2 | 2011 | 177 | 0.140 |
Why?
| | Infant, Newborn | 1 | 2026 | 2871 | 0.140 |
Why?
| | Public Health Surveillance | 1 | 2018 | 18 | 0.140 |
Why?
| | Thiazoles | 2 | 2016 | 53 | 0.140 |
Why?
| | Sleep Deprivation | 1 | 2018 | 18 | 0.140 |
Why?
| | Papillomavirus Vaccines | 1 | 2019 | 69 | 0.140 |
Why?
| | Pharmacies | 1 | 2019 | 61 | 0.140 |
Why?
| | Physicians | 1 | 2021 | 237 | 0.140 |
Why?
| | Risk Assessment | 3 | 2025 | 1349 | 0.140 |
Why?
| | Chronic Disease | 5 | 2011 | 579 | 0.140 |
Why?
| | Metabolic Diseases | 1 | 2018 | 48 | 0.130 |
Why?
| | Veterans Health | 2 | 2014 | 61 | 0.130 |
Why?
| | Molecular Weight | 1 | 2017 | 78 | 0.130 |
Why?
| | Acute Pain | 1 | 2017 | 12 | 0.130 |
Why?
| | Coronary Vessels | 1 | 2019 | 169 | 0.130 |
Why?
| | Papillomavirus Infections | 1 | 2019 | 170 | 0.130 |
Why?
| | Coronary Angiography | 1 | 2019 | 367 | 0.130 |
Why?
| | Fractional Flow Reserve, Myocardial | 1 | 2019 | 127 | 0.130 |
Why?
| | Educational Measurement | 1 | 2018 | 196 | 0.130 |
Why?
| | Eosinophils | 1 | 2017 | 39 | 0.130 |
Why?
| | Monte Carlo Method | 1 | 2016 | 89 | 0.130 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 185 | 0.120 |
Why?
| | Chilaiditi Syndrome | 1 | 2015 | 1 | 0.120 |
Why?
| | Education, Pharmacy | 1 | 2018 | 156 | 0.120 |
Why?
| | Anti-Bacterial Agents | 1 | 2002 | 816 | 0.120 |
Why?
| | Incidental Findings | 1 | 2015 | 43 | 0.120 |
Why?
| | Geriatrics | 1 | 2016 | 41 | 0.120 |
Why?
| | India | 1 | 2015 | 60 | 0.120 |
Why?
| | Health Services Accessibility | 1 | 2020 | 444 | 0.120 |
Why?
| | Sex Distribution | 1 | 2015 | 138 | 0.110 |
Why?
| | Health Policy | 3 | 2011 | 162 | 0.110 |
Why?
| | Models, Theoretical | 1 | 2016 | 181 | 0.110 |
Why?
| | Sulfides | 1 | 2015 | 29 | 0.110 |
Why?
| | Cyclopropanes | 1 | 2015 | 27 | 0.110 |
Why?
| | Thrombosis | 1 | 2018 | 250 | 0.110 |
Why?
| | Pyridines | 1 | 2016 | 137 | 0.110 |
Why?
| | Income | 1 | 2015 | 106 | 0.110 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 198 | 0.110 |
Why?
| | Anti-Asthmatic Agents | 1 | 2015 | 33 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 323 | 0.110 |
Why?
| | Societies, Medical | 1 | 2016 | 200 | 0.110 |
Why?
| | Sarcopenia | 1 | 2015 | 99 | 0.110 |
Why?
| | Self Report | 1 | 2016 | 221 | 0.110 |
Why?
| | Long-Term Care | 3 | 2012 | 50 | 0.110 |
Why?
| | Educational Status | 1 | 2015 | 227 | 0.110 |
Why?
| | SEER Program | 2 | 2025 | 105 | 0.110 |
Why?
| | Disease Progression | 1 | 2017 | 870 | 0.100 |
Why?
| | Enoxaparin | 2 | 2025 | 31 | 0.100 |
Why?
| | California | 2 | 2004 | 92 | 0.100 |
Why?
| | Comorbidity | 5 | 2017 | 637 | 0.100 |
Why?
| | Health Literacy | 1 | 2015 | 131 | 0.100 |
Why?
| | Health Behavior | 1 | 2015 | 256 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2013 | 122 | 0.100 |
Why?
| | Prescriptions | 2 | 2011 | 11 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 871 | 0.100 |
Why?
| | Infant | 3 | 2011 | 3709 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2004 | 404 | 0.090 |
Why?
| | Managed Care Programs | 1 | 2012 | 36 | 0.090 |
Why?
| | Ticlopidine | 1 | 2012 | 71 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 938 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 625 | 0.090 |
Why?
| | Deductibles and Coinsurance | 1 | 2011 | 2 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 102 | 0.080 |
Why?
| | Incidence | 3 | 2025 | 1096 | 0.080 |
Why?
| | Body Mass Index | 2 | 2013 | 701 | 0.080 |
Why?
| | Calibration | 1 | 2009 | 56 | 0.080 |
Why?
| | International Classification of Diseases | 1 | 2009 | 70 | 0.080 |
Why?
| | Clozapine | 2 | 2010 | 25 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2010 | 558 | 0.070 |
Why?
| | Reference Values | 1 | 2009 | 316 | 0.070 |
Why?
| | Treatment Refusal | 1 | 2009 | 35 | 0.070 |
Why?
| | Carbamazepine | 1 | 2007 | 13 | 0.070 |
Why?
| | Lithium Compounds | 1 | 2007 | 12 | 0.070 |
Why?
| | Mental Health | 1 | 2010 | 237 | 0.070 |
Why?
| | Alendronate | 1 | 2007 | 24 | 0.070 |
Why?
| | Fractures, Spontaneous | 1 | 2007 | 15 | 0.070 |
Why?
| | Valproic Acid | 1 | 2007 | 35 | 0.070 |
Why?
| | Internationality | 3 | 2014 | 46 | 0.070 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2007 | 122 | 0.060 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2007 | 30 | 0.060 |
Why?
| | Affect | 1 | 2007 | 107 | 0.060 |
Why?
| | Drug Labeling | 1 | 2006 | 11 | 0.060 |
Why?
| | Bone Density Conservation Agents | 1 | 2007 | 75 | 0.060 |
Why?
| | Data Collection | 2 | 2009 | 285 | 0.060 |
Why?
| | Adrenergic beta-Agonists | 1 | 2005 | 39 | 0.060 |
Why?
| | Self Disclosure | 1 | 2005 | 13 | 0.060 |
Why?
| | Australia | 1 | 2025 | 97 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 112 | 0.060 |
Why?
| | Drug Interactions | 2 | 2018 | 198 | 0.060 |
Why?
| | Depression | 1 | 2009 | 603 | 0.050 |
Why?
| | Factor Analysis, Statistical | 1 | 2004 | 89 | 0.050 |
Why?
| | Eligibility Determination | 1 | 2004 | 22 | 0.050 |
Why?
| | Urban Population | 1 | 2005 | 161 | 0.050 |
Why?
| | Health Surveys | 2 | 2018 | 238 | 0.050 |
Why?
| | Prescription Fees | 1 | 2004 | 14 | 0.050 |
Why?
| | Length of Stay | 1 | 2007 | 673 | 0.050 |
Why?
| | Algorithms | 1 | 2007 | 673 | 0.050 |
Why?
| | Laparoscopy | 1 | 2025 | 180 | 0.050 |
Why?
| | Data Interpretation, Statistical | 3 | 2009 | 166 | 0.050 |
Why?
| | MEDLINE | 1 | 2002 | 8 | 0.050 |
Why?
| | Prospective Studies | 1 | 2008 | 2433 | 0.050 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2002 | 28 | 0.050 |
Why?
| | Neuropsychological Tests | 1 | 2003 | 346 | 0.050 |
Why?
| | Analgesics | 1 | 2023 | 106 | 0.050 |
Why?
| | Quality of Life | 2 | 2023 | 893 | 0.050 |
Why?
| | Cognition Disorders | 1 | 2003 | 213 | 0.050 |
Why?
| | Pharmacy | 2 | 2018 | 54 | 0.040 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2022 | 91 | 0.040 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2020 | 50 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 141 | 0.040 |
Why?
| | Ohio | 1 | 2019 | 46 | 0.040 |
Why?
| | Myocardial Revascularization | 1 | 2019 | 29 | 0.040 |
Why?
| | Quality of Health Care | 1 | 2020 | 186 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2017 | 7 | 0.030 |
Why?
| | Universities | 1 | 2018 | 174 | 0.030 |
Why?
| | Research Design | 2 | 2014 | 368 | 0.030 |
Why?
| | Vaccination | 1 | 2019 | 294 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 725 | 0.030 |
Why?
| | Communication | 1 | 2018 | 255 | 0.030 |
Why?
| | Qualitative Research | 1 | 2018 | 365 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2018 | 274 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2018 | 358 | 0.030 |
Why?
| | Survival Analysis | 1 | 2014 | 656 | 0.020 |
Why?
| | Ischemic Attack, Transient | 1 | 2013 | 60 | 0.020 |
Why?
| | Lipids | 1 | 2013 | 163 | 0.020 |
Why?
| | Linear Models | 1 | 2013 | 288 | 0.020 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2012 | 40 | 0.020 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2017 | 393 | 0.020 |
Why?
| | Diagnostic Tests, Routine | 1 | 2012 | 31 | 0.020 |
Why?
| | Cost Control | 1 | 2011 | 13 | 0.020 |
Why?
| | Blood Pressure | 1 | 2013 | 525 | 0.020 |
Why?
| | Acute Coronary Syndrome | 1 | 2012 | 106 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2005 | 1223 | 0.020 |
Why?
| | Dibenzothiazepines | 1 | 2010 | 10 | 0.020 |
Why?
| | Adolescent Behavior | 1 | 2011 | 107 | 0.020 |
Why?
| | Hypnotics and Sedatives | 1 | 2010 | 73 | 0.020 |
Why?
| | Off-Label Use | 1 | 2010 | 24 | 0.020 |
Why?
| | Observation | 1 | 2009 | 8 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 2009 | 47 | 0.020 |
Why?
| | Causality | 1 | 2009 | 51 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2013 | 318 | 0.020 |
Why?
| | Mood Disorders | 1 | 2009 | 60 | 0.020 |
Why?
| | Quinolones | 1 | 2010 | 54 | 0.020 |
Why?
| | Anxiety Disorders | 1 | 2009 | 128 | 0.020 |
Why?
| | Piperazines | 1 | 2010 | 125 | 0.020 |
Why?
| | ROC Curve | 1 | 2009 | 249 | 0.020 |
Why?
| | Headache | 1 | 2008 | 74 | 0.020 |
Why?
| | Sex Factors | 1 | 2009 | 735 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2007 | 158 | 0.020 |
Why?
| | Probability | 1 | 2007 | 171 | 0.020 |
Why?
| | Drug Utilization Review | 1 | 2005 | 22 | 0.010 |
Why?
| | Bone Density | 1 | 2007 | 396 | 0.010 |
Why?
| | Drug Monitoring | 1 | 2005 | 81 | 0.010 |
Why?
| | Registries | 1 | 2007 | 638 | 0.010 |
Why?
| | Health Maintenance Organizations | 1 | 2002 | 16 | 0.010 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2002 | 28 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 2002 | 94 | 0.010 |
Why?
|
|
Martin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|